Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Ipragliflozin25 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A01937 | 34558835 | Hepatol Commun | Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. | 2021 | Details |
| A03995 | 33798599 | Eur J Pharmacol | Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH. | 2021 | Details |
| A04857 | 33479589 | Diabetol Int | Improved insulin sensitivity with sodium-glucose cotransporter 2 inhibitor treatment in a patient with slowly progressive type 1 diabetes mellitus with metabolic syndrome: a case report. | 2020 | Details |
| A05042 | 33396949 | Metabolites | Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. | 2020 | Details |
| A08737 | 32006266 | Adv Exp Med Biol | Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. | 2021 | Details |
| A08856 | 31963648 | J Clin Med | Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. | 2020 | Details |
| A08871 | 31955626 | Endocr Res | Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice. | 2020 | Details |
| A09056 | 31888083 | Int J Mol Sci | Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules. | 2019 | Details |
| A09349 | 31782258 | Physiol Rep | SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model. | 2019 | Details |
| A12555 | 30393249 | Endocr J | Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results). | 2018 | Details |
| A12902 | 30234161 | Open Med (Wars) | Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease. | 2018 | Details |
| A15414 | 28924123 | Intern Med | The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin. | 2017 | Details |
| A15703 | 28751548 | Diabetes Care | Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. | 2017 | Details |
| A17124 | 27980239 | Endocr J | Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. | 2016 | Details |
| A18736 | 26977813 | PLoS One | Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. | 2016 | Details |
| A18829 | 26914659 | Clin Drug Investig | Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors. | 2016 | Details |
| A19142 | 26731267 | PLoS One | The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. | 2016 | Details |
| A20839 | 25701721 | Eur J Pharmacol | Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. | 2015 | Details |
| A28645 | 35192632 | PLoS One | Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model. | 2022 | Details |
| A31250 | 30962742 | Yonago Acta Med | Protective Effects of Ipragliflozin, a Sodium-glucose Cotransporter 2 Inhibitor, on a Non-alcoholic Steatohepatitis Mouse Model. | 2019 | Details |
| A43009 | 32821334 | World J Hepatol | Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling. | 2020 | Details |
| A49924 | 35593157 | Hepatol Commun | Reply to: "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD". | 2022 | Details |
| A50091 | 35531591 | Hepatol Commun | Reply to the Letter to the editor "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD". | 2022 | Details |
| A50745 | 35280867 | Front Med (Lausanne) | Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. | 2022 | Details |
| A50978 | 29202593 | Expert Opin Pharmacother | Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won? | 2017 | Details |